Skip to main content
Premium Trial:

Request an Annual Quote

LGC Acquires Link Technologies

NEW YORK (GenomeWeb) – Life sciences tools provider LGC said today that it has acquired Link Technologies, a supplier of specialty reagents for oligonucleotide synthesis.

Following the acquisition, LGC plans to form a new Nucleic Acid Chemistry business unit within its Genomics division that combines Link with its existing Biosearch oligo reagent group and Prime Synthesis CPG business.

Brian Kim, president and managing director of the LGC Genomics division, said in a statement that Link's products are a "great complement" to LGC's, and will provide customers with "an expanded product range, increased supply chain security, improved global logistics, and industry-leading customer support."

Link's customers include oligo synthesis companies, university and commercial research departments, and others in the biotech sector, LGC added.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.